Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented.The…
Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may…
BASEL, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system…
The American Society for Clinical Oncology to be held in Chicago May 29 – June 2, 2026 March 31, 2026…
February 23, 2026 17:10 ET | Source: Kyntra Bio FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen…
Global oncology society calls for abstract submissions for research that is shaping the future of cancer care in advance of…
Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib June 20,…
New solution improves protocol design, reduces patient- and site-burden, accelerates recruitment, and delivers increased efficiencies for clinical trials SINGAPORE, June…